Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesFibroGen Inc

FibroGen Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-02-12T21:10:09.359412Z
Market Cap
129.32M

Momentum Score

…

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.33
Low
19.47
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
167.49M
Revenue Per Share
1.70
Gross Profit TTM
-159.21M
Debt / Equity
-0.83
ROE
-1015.79%
Net Debt
56.77M
ROCE
-146.23%
Diluted EPS TTM
-2.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -294.87M -290.68M -188.93M -76.64M -86.12M
Minority interest - - 19.27M 19.27M 19.27M
Net income -295.23M -291.03M -189.29M -76.97M -86.42M
Selling general administrative 124.69M 123.92M 106.41M 135.48M 63.81M
Gross profit 120.45M 222.44M 167.45M 255.43M 212.96M
Reconciled depreciation 10.60M 14.81M 22.05M 21.45M 6.56M
Ebit -301.02M -303.34M -191.88M -89.31M -81.69M
Ebitda -282.82M -288.53M -186.33M -73.77M -75.12M
Depreciation and amortization 18.20M 14.81M 5.55M 15.55M 6.56M
Non operating income net other - 1.01M - - -
Operating income -301.02M -288.53M -191.88M -89.31M -86.69M
Other operating expenses 441.76M 523.84M 368.20M 345.89M 299.65M
Interest expense 1.44M 2.15M 2.40M 2.88M 10.99M
Tax provision 0.36M 0.35M 0.36M 0.33M 0.30M
Interest income 7.60M - 5.55M 15.55M 11.57M
Net interest income 6.16M -2.15M 3.15M 12.67M 0.58M
Income tax expense 0.36M 0.35M 0.36M 0.33M 0.30M
Total revenue 140.73M 235.31M 176.32M 256.58M 212.96M
Total operating expenses 421.48M 510.97M 359.33M 344.74M 299.65M
Cost of revenue 20.28M 12.87M 8.87M 1.15M 235.84M
Total other income expense net 6.16M -2.15M 2.95M 12.67M 0.58M
Net income from continuing ops -293.65M -290.02M -189.29M -76.97M -86.42M
Net income applicable to common shares -293.65M -290.02M -189.29M -76.97M -86.42M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 423.53M 610.09M 773.82M 826.84M 857.40M
Other current assets 13.36M 4.35M 5.07M 1.81M 133.39M
Total liab 585.73M 611.57M 544.71M 385.39M 321.99M
Total stockholder equity -204.17M -21.45M 209.15M 422.18M 516.13M
Other current liab 172.85M 219.38M 172.59M 119.52M 83.82M
Common stock 0.99M 0.94M 0.93M 0.91M 0.88M
Capital stock 0.99M 0.94M 0.93M 0.91M 0.88M
Retained earnings -1841.92M -1557.69M -1264.03M -974.01M -784.72M
Other liab - 241.36M 212.82M 178.12M 162.77M
Other assets 0.00M 6.92M 7.99M 38.08M 9.51M
Cash 113.69M 155.70M 171.22M 678.39M 126.27M
Total current liabilities 217.67M 273.56M 225.50M 163.19M 102.75M
Current deferred revenue 12.74M 13.13M 15.86M 6.55M 0.49M
Net debt 56.77M -65.81M -71.49M -640.67M -75.16M
Short term debt 14.12M 10.29M 10.96M 12.33M 12.35M
Short long term debt total 170.46M 89.89M 99.73M 37.72M 51.10M
Other stockholder equity 1643.64M 1541.02M 1476.41M 1399.77M 1300.72M
Property plant equipment - 100.93M 120.15M 33.65M 42.74M
Total current assets 331.56M 492.83M 474.06M 755.11M 702.49M
Long term investments 5.29M 9.41M 171.62M 0.24M 61.12M
Net tangible assets - -21.45M 209.15M 422.18M 516.13M
Short term investments 121.90M 266.31M 233.97M 8.14M 407.49M
Net receivables 41.05M 16.30M 17.40M 41.88M 28.45M
Long term debt 71.93M - - - 16.78M
Inventory 41.56M 40.44M 31.02M 16.53M 6.89M
Accounts payable 17.96M 30.76M 26.10M 24.79M 6.09M
Noncontrolling interest in consolidated entity - - 19.97M 19.27M 19.27M
Accumulated other comprehensive income -6.88M -5.72M -4.16M -4.50M -0.75M
Common stock total equity - - 0.93M 0.91M 0.88M
Retained earnings total equity - - -1264.03M -974.01M -784.72M
Non currrent assets other 3.65M 7.35M 7.99M 5.50M 11.44M
Non current assets total 91.97M 117.26M 299.76M 71.73M 154.91M
Capital lease obligations 80.61M 89.89M 99.73M 38.57M 49.96M
Long term debt total - - - - 55.53M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 89.12M -396.79M 467.51M 537.07M 62.59M
Change to liabilities 1.78M 58.44M 20.54M 67.60M 10.90M
Total cashflows from investing activities 89.12M -426.97M 452.49M 120.02M -522.12M
Net borrowings -0.54M -5.89M -0.40M -0.40M -0.36M
Total cash from financing activities 46.78M -0.56M 13.34M -4.30M 13.88M
Change to operating activities 78.89M -9.38M 132.97M -61.01M 8.23M
Net income -293.65M -290.02M -189.29M -76.97M -86.42M
Change in cash -15.52M -507.17M 552.13M 37.01M -584.40M
Begin period cash flow 171.22M 678.39M 126.27M 89.26M 673.66M
End period cash flow 155.70M 171.22M 678.39M 126.27M 89.26M
Total cash from operating activities -145.93M -82.23M 81.60M -78.70M -76.14M
Issuance of capital stock 4.18M 12.70M 37.83M 20.78M 29.85M
Depreciation 10.60M 14.81M 22.05M 21.45M 6.56M
Other cashflows from investing activities - -20.79M -11.03M -411.29M -576.70M
Change to inventory -11.00M -14.16M -9.18M -6.89M 8.23M
Change to account receivables 0.77M 25.18M -11.97M 35.23M -55.23M
Sale purchase of stock - 12.70M 37.83M 20.78M 29.85M
Other cashflows from financing activities 43.13M -7.37M -11.46M -12.75M -15.56M
Change to netincome 66.69M 132.90M 73.91M 66.22M 51.03M
Capital expenditures 38.74M 30.19M 3.99M 5.76M 8.02M
Change receivables - 25.18M -11.97M 35.23M -55.23M
Cash flows other operating - 47.63M 185.81M -171.38M -2.95M
Cash and cash equivalents changes - -509.77M 547.43M 37.01M -584.39M
Change in working capital 70.43M 60.08M 174.63M -85.66M -48.40M
Stock based compensation 65.60M 71.16M 72.72M 66.27M 52.14M
Other non cash items 1.09M 60.00M 0.20M -0.09M -0.03M
Free cash flow -184.67M -112.42M 77.61M -84.47M -84.16M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

409 Illinois Street, San Francisco, CA, United States, 94158

415 978 1200

https://www.fibrogen.com

486

Name Title Year Born
Mr. Enrique A. Conterno CEO & Director 1967
Mr. Juan Graham Chief Financial Officer 1976
Dr. Elias Kouchakji Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance 1956
Ms. Christine L. Chung Sr. VP of China Operations 1968
Mr. Thane Wettig Exec. VP & Chief Commercial Officer 1965
Dr. Mark Eisner M.D., M.P.H. Exec. VP & Chief Medical Officer 1966
Dr. Barry A. Berkowitz Ph.D. Founder NA
Dr. John J. Hunter Ph.D. Chief Scientific Officer 1963
Ms. Karen L. Bergman VP of Investor Relations & Corp. Communications NA
Mr. Michael D. Lowenstein J.D., Ph.D. Chief Legal Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…